KDR and neoplasm: Apatinib is a novel small-molecule tyrosine kinase inhibitor (TKI) that highly selectively competes for the associated binding sites of VEGFR-2 to inhibit its phosphorylation and the generation of vascular endothelial cells and tumor vessels.